Genscript Biotech Corporation (01548) published its monthly return for the equity issuer for January 2026 on 3 February 2026. The authorized share capital remained at 5,000,000,000 ordinary shares, each with a par value of USD 0.001, totaling USD 5,000,000.
The issued share count (excluding treasury shares) increased by 140,000 compared to the prior month, resulting in a closing balance of 2,186,518,520 issued shares. The new shares were issued through the Post-IPO Share Option Scheme, raising HKD 336,840 in total. The company confirmed that its public float level continues to meet the 25% requirement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments